

**REMARKS/ARGUMENTS**

Favorable consideration of this application is respectfully requested.


Submitted herewith is a Declaration by Abdul Sattar, Translational Pharmacology Manager at Renovo Limited, owner of the above-identified application. The Declaration includes the results of a study conducted at the direction of the declarant and under his supervision. The data provided in the Declaration correspond to the data presented in the Appendix that was filed with the May 28, 2008 Amendment. The results presented make it clear that Matrani does not disclose the use of activin in an amount sufficient to promote the healing of a wound or fibrotic disorder with reduced macroscopic scarring.

This application is submitted to be in condition for allowance and a Notice to that effect is requested.

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By:



Mary J. Wilson  
Reg. No. 32,955

MJW:tat  
901 North Glebe Road, 11th Floor  
Arlington, VA 22203-1808  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100